İsmail HARMANKAYA, Nevzat Serdar UĞRAŞ, Sümeyye Nur TATAROĞLU

TROP2 and SOX-10 expression in the differential diagnosisof bladder tumors

Aim: TROP2 is a member of the calcium signal converting gene family, which is highly expressed in various cancers. SOX10 is the nuclear transcription factor associated with the formation and development of various cancers. We investigated the importance of TROP2 and SOX10 in the differential diagnosis of tumoral lesions of the bladder.Materials and Methods: TROP2 and SOX10 expressions were evaluated by immunohistochemical method in 150 tumoral and 20 non-tumoral bladder tissues.Results: Strong staining with TROP2 was frequently seen in cases of papillary urothelial neoplasm with low malignant potential. There was no significant difference in the intensity of staining between the nontumoral group and the carcinoma groups, and between noninvasive carcinomas and invasive carcinomas.Conclusion: Although strong staining with TROP2 indicates tumoral development, widespread staining does not show this. Expression loss in TROP2 is observed in muscle invasive carcinomas. Strong and widespread (≥ 50%) TROP2 staining indicates papillary urothelial neoplasm with low malignant potential. Evaluation of this finding together with histomorphological findings may help to make an accurate diagnosis.

PDF

___

1. Solomon JP, Hansel DE. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Adv Anat Pathol 2015;22:102-12.
2. Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers 2017,3:17022.
3. Narter F, Tarhan F, Saglam E, et al. Importance of the Re-Transurethral Resection in Bladder Cancer Treatment. Bullet of Urooncol 2016;15:94-7.
4. Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet 2016;388:2796-810.
5. Yin H, Qin C, Zhao Y, et al. SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors. Clin Transl Oncol 2017;19:1035-44.
6. Avellini C, Licini C, Lazzarini R, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget 2017;8:58642-53.
7. Wang G, McKenney JK. Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med 2019;143:571-7.
8. Zhang L, Yang G, Zhang R, et al. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncolog 2018;53:515-26.
9. Tang G, Tang Q, Jia L, et al. High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma.Pathol Res Pract 2018;214:1606-12.
10. Zhao W, Ding G, Wen J, et al. Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer. Cancer Med 2017;6:994-1001.
11. Wu B, Yu C, Zhou B, et al. Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells. Exp Ther Med 2017;14:1947-52.
12. Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep 2018;40:759-66.
13. Yang X, Hu Y, Shi H, et al. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur Arch Otorhinolaryngol 2018;275:2127-34.
14. Murtezaoglu AR, Gucer H. Diagnostic value of TROP2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19. Pol J Pathol 2017;68:1-10.
15. Liu H, Shi J, Lin F. The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms. Appl Immunohistochem Mol Morphol 2017;25:525-33.
16. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget 2017;8:28725-35.
17. Li Z, Jiang X, Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun 2016;470:197- 204.
18. Guan GF, Zhang DJ, Wen LJ, et al. Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Patho 2015;8:10995-1004.
19. Kato M, Nishihara H, Hayashi H, et al. Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. Medical Oncology 2017;34:8.
20. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol 2015;39:826-35.
21. Willis BC, Johnson G, Wang J, Cohen C: SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol 2015;23:109-12.
22. Lezcano C, Ho J, Seethala RR. Sox10 and DOG1 Expression in Primary Adnexal Tumors of the Skin. Am J Dermatopathol 2017;39:896-902.
23. Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol 2012;20:445-50.
24. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE: The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 2016;70:106- 19.
25. Zaman S, Jadid H, Denson AC, Gray JE: Targeting Trop-2 in solid tumors: future prospects. OncoTargets Ther 2019;12:1781-90.